James L. Abbruzzese

Duke Medical Center

Full Professor(heuristic)

Pancreatic and Hepatic Oncology Research · Oncology

Compare more Oncology professors.

h-index129
i10-index449
Publications784
Citations59,215

Grants

8 total · 0 active

NIH #R21CA257816

Adapting K-MDS to detect KRAS-mutant ctDNA

Amount
$100K–$200K
Period
2022-09-21 → 2025-08-31
PIs
2

Awarded at DUKE UNIVERSITY

NIH #P30CA014236

Clinical Protocol and Data Management

Amount
$300K–$400K
Period
1997-01-01 → 2025-04-17
PIs
1

Awarded at DUKE UNIVERSITY

NIH #UM1CA186704

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Amount
$1M–$2M
Period
2014-04-04 → 2020-02-29
PIs
3

Awarded at DUKE UNIVERSITY

Active grants are a starting point, not proof of an opening. Confirm recruiting and funding with the professor, current students, and your written offer. Learn how to verify PhD funding →

All Grants

8 total · 0 active

NIH #R21CA257816

Adapting K-MDS to detect KRAS-mutant ctDNA

Amount
$100K–$200K
Period
2022-09-21 → 2025-08-31
PIs
2

Awarded at DUKE UNIVERSITY

NIH #P30CA014236

Clinical Protocol and Data Management

Amount
$300K–$400K
Period
1997-01-01 → 2025-04-17
PIs
1

Awarded at DUKE UNIVERSITY

NIH #UM1CA186704

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Amount
$1M–$2M
Period
2014-04-04 → 2020-02-29
PIs
3

Awarded at DUKE UNIVERSITY

NIH #P20CA101936

SPORE in Pancreatic Cancer

Amount
$1M–$2M
Period
2003-09-30 → 2008-08-31
PIs
1

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #U54CA090810

Targeted Assessment of Antiangiogenic Therapy

Amount
$1M–$2M
Period
2001-07-16 → 2006-12-31
PIs
1

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #U01CA062461

CORRELATED CLINICAL-LABORATORY PHASE I TRIALS

Amount
$600K–$700K
Period
1994-03-01 → 2003-01-31
PIs
1

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #U01CA070172

PHASE II/III CLINICAL TRIALS OF ANTICANCER AGENTS

Amount
$400K–$500K
Period
1995-08-01 → 2002-11-30
PIs
1

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #R03CA053398

HUMAN TOPO I--AN EXPLOITABLE ANTICANCER DRUG TARGET

Amount
<$100K
Period
1991-09-30 → 1992-12-31
PIs
1

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

Recent Public Signals

  1. New paper: Use of an ultra-sensitive sequencing platform to detect mutant <i>KRAS</i> in the whole blood of pancreatic cancer patients. (Journal of Clinical Oncology)2025-05-28
  2. New preprint: Supplementary Figure S1 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants2025-01-09

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

Data Freshness

  • Publications as of 2026-07-09
  • Grants as of 2026-08-23

Data may not be current

Find elsewhere

Institution / lab homepage Search on ResearchGate

ORCID: 0000-0001-9223-2965

Professor Insights

Career Trajectory